Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Level2View

ANNX
Annexon, Inc. Common Stock
stock NASDAQ

At Close
Jul 17, 2025 3:59:56 PM EDT
2.33USD-2.917%(-0.07)1,754,669
0.00Bid   0.00Ask   0.00Spread
Pre-market
Jul 17, 2025 9:25:30 AM EDT
2.40USD0.000%(0.00)3,817
After-hours
Jul 17, 2025 4:46:30 PM EDT
2.37USD+1.717%(+0.04)3,389
OverviewOption ChainMax PainOptionsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 20, 2022
06:30AM EST  Annexon Biosciences Appoints Bettina M. Cockroft, M.D. to its   GlobeNewswire Inc
Jan 5, 2022
02:30PM EST  Mid-Afternoon Market Update: Nasdaq Down 300 Points; Annexon Shares Plunge   Benzinga
12:05PM EST  Mid-Day Market Update: Nasdaq Tumbles Over 100 Points; Mainz Biomed Shares Climb   Benzinga
10:13AM EST  Mid-Morning Market Update: Markets Edge Lower; RPM International Posts Mixed Q2 Results   Benzinga
08:20AM EST  The Daily Biotech Pulse: Pfizer-BioNTech Partner For Shingles Vaccine, Annexon Huntington Disease Study Disappoints, Amneal Buys Neurology Assets   Benzinga
Jan 4, 2022
04:09PM EST  Annexon Biosciences Reports Interim Phase 2 Data Showing ANX005 'Has Been Generally Well-Tolerated and Has Shown Full Target Engagement of C1q in the CSF'   Benzinga
04:05PM EST  ANX005 Has Been Generally Well-Tolerated and Has Shown Full Target Engagement of C1q in the CSF   GlobeNewswire Inc
06:30AM EST  Annexon Biosciences to Present at the 40th Annual J.P. Morgan   GlobeNewswire Inc
Dec 13, 2021
09:19AM EST  Annexon Biosciences Announces Clinical, Preclinical Data Highlighting Potential Of Complement-Targeting Programs At ASH 2021 Meeting   Benzinga
09:00AM EST  Annexon Biosciences Announces Clinical and Preclinical Data   GlobeNewswire Inc
Nov 30, 2021
04:51PM EST  Benzinga's Top Ratings Upgrades, Downgrades For November 30, 2021   Benzinga
04:42PM EST  HC Wainwright & Co. Initiates Coverage On Annexon with Buy Rating, Announces Price Target of $40   Benzinga
Nov 9, 2021
04:17PM EST  Annexon Q3 EPS $(0.93) Down From $(0.77) YoY   Benzinga
Oct 4, 2021
06:41AM EDT  Annexon Biosciences Appoints Ted Yednock As Chief Innovation Officer And Larry Mattheakis As Chief Scientific Officer   RTTNews
06:30AM EDT  Dr. Ted Yednocks appointment enhances Annexons commitment to scientific innovation and pursuit of future programs   GlobeNewswire Inc
Sep 23, 2021
10:06AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For September 23, 2021   Benzinga
07:39AM EDT  Cantor Fitzgerald Initiates Coverage On Annexon with Overweight Rating, Announces Price Target of $40   Benzinga
06:34AM EDT  Annexon Biosciences To Participate In 2021 Cantor Virtual Global Healthcare Conference Sept. 30   Benzinga
06:30AM EDT  Annexon Biosciences to Participate in 2021 Cantor Virtual Global   GlobeNewswire Inc
Sep 20, 2021
06:30AM EDT  Annexon Biosciences to Highlight Neurodegeneration Franchise in   GlobeNewswire Inc
Aug 20, 2021
07:45AM EDT  The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data   Benzinga
Aug 16, 2021
05:23PM EDT  Annexon Filing Shows Registration For $100M Mixed Securities Shelf Offering   Benzinga
04:03PM EDT  Annexon Q2 EPS $(0.82) Up From $(28.87) YoY   Benzinga
04:01PM EDT  Recently expanded Autoimmune franchise with advancement of third clinical candidate, ANX009, and strategically expanded into additional autoantibody-driven diseases   GlobeNewswire Inc
Jul 22, 2021
07:16AM EDT  Annexon Broadens Autoimmune Franchise with Advancement of Third Anti-C1q Product Candidate and Strategic Expansion into New Autoantibody-driven Diseases   Benzinga
07:00AM EDT  Advancing subcutaneous ANX009 candidate into Phase 1b program in Lupus Nephritis   GlobeNewswire Inc
Jun 16, 2021
07:00AM EDT  Annexon to Present at the Raymond James Human Health Innovation   GlobeNewswire Inc
May 17, 2021
04:23PM EDT  Annexon Q1 EPS $(0.68) Up From $(29.10) YoY   Benzinga
04:05PM EDT  ANX005 Huntingtons Disease Phase 2 trial fully enrolled with data anticipated 2H 2021   GlobeNewswire Inc
May 5, 2021
07:27AM EDT  Annexon To Present At BofA Securities 2021 Virtual Healthcare Conference May 12   Benzinga
07:00AM EDT  Annexon to Present at the BofA Securities 2021 Virtual Healthcare   GlobeNewswire Inc
Mar 25, 2021
07:08AM EDT  Annexon Q4 EPS $(0.61) Misses $(0.44) Estimate   Benzinga
07:00AM EDT  Today Annexon, Inc. (Annexon) (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain and eye, announced fourth quarter and full-year 2020 financial results and business highlights.   GlobeNewswire Inc
Mar 1, 2021
01:11PM EST  Annexon Shares Gain After Patient Dosing Starts In Mid-Stage Study For Vision Loss Disorder Therapy   Benzinga
07:14AM EST  Annexon Begins Dosing of its Phase 2 ARCHER Study of ANX007 to Treat Geographic Atrophy   Benzinga
07:00AM EST  Annexon Advances Classical Complement Platform with Initiation of   GlobeNewswire Inc
Feb 23, 2021
07:25AM EST  The Daily Biotech Pulse: Aridis To Study Antibody Cocktail For Coronavirus Variants, Revance & Protalix Data Readouts   Benzinga
Feb 8, 2021
07:11AM EST  Annexon Adds William Carson To Board   RTTNews
07:10AM EST  Annexon Appoints William Carson To Its Board   RTTNews
07:00AM EST  Annexon Welcomes William H. Carson, M.D. to the Board of Directors   GlobeNewswire Inc
Jan 26, 2021
10:03AM EST  Benzinga's Top Ratings Upgrades, Downgrades For January 26, 2021   Benzinga
05:53AM EST  Needham Initiates Coverage On Annexon with Buy Rating, Announces Price Target of $37   Benzinga
Jan 19, 2021
11:11PM EST  The lockup period of South San Francisco, California-based Annexon (ANNX) expires tomorrow, i.e., on January 20.   RTTNews
Jan 12, 2021
07:00AM EST  Annexon Highlights Recent Achievements and Outlines Expected Key   GlobeNewswire Inc
Jan 5, 2021
07:00AM EST  Annexon to Present at the J.P. Morgan 39th Annual Healthcare   GlobeNewswire Inc
Dec 21, 2020
07:16AM EST  Annexon Begins Phase 2/3 Trial Of ANX005 In Patients With Guillain-Barr Syndrome   RTTNews
07:12AM EST  Annexon Announces Initiation of Phase 2/3 Trial of ANX005 in Patients with Guillain-Barr Syndrome   Benzinga
07:00AM EST  Annexon Announces Initiation of Phase 2/3 Trial of ANX005 in   GlobeNewswire Inc
Nov 16, 2020
04:07PM EST  Annexon Q3 EPS $(0.77) Misses $(0.35) Estimate   Benzinga
04:01PM EST  Cash balance of $370.7 million as of September 30, 2020 bolstered by July IPO Recently expanded ANX005 clinical program into neurodegeneration, with initiation of Phase 2 in Huntingtons Disease Fully enrolled Phase 1b DDI trial in Guillain-Barr Syndrome   GlobeNewswire Inc
Nov 12, 2020
04:05PM EST  Annexon Expands Classical Complement Platform into   GlobeNewswire Inc
Sep 8, 2020
04:19PM EDT  Annexon Biosciences Q2 Loss/share $28.87 Vs. Loss $22.30 Year Ago   RTTNews
04:06PM EDT  Annexon Biosciences Reports Q2 2020 EPS $(28.97)   Benzinga
04:01PM EDT  Annexon Biosciences Reports Second Quarter 2020 Financial Results   GlobeNewswire Inc
Aug 18, 2020
09:48AM EDT  Benzinga's Top Upgrades, Downgrades For August 18, 2020   Benzinga
06:48AM EDT  B of A Securities Initiates Coverage On Annexon with Buy Rating, Announces Price Target of $33   Benzinga
06:10AM EDT  Cowen & Co. Initiates Coverage On Annexon with Outperform Rating   Benzinga
Aug 13, 2020
08:18AM EDT  The Daily Biotech Pulse: Mesoblast Awaits Adcom Test, BioCryst Rallies On Insider Buying, Sorrento Hits Back At Short Seller   Benzinga
Aug 6, 2020
07:57AM EDT  The Daily Biotech Pulse: FDA Nod For GlaxoSmithKline, Bristol-Myers Squibb Earnings, Acutus Medical IPO   Benzinga
07:19AM EDT  Biocryst Pharmaceuticals Q2 EPS $(0.24) Beats $(0.25) Estimate   Benzinga
Jul 30, 2020
08:00AM EDT  Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain and eye, today announced the appointment of Michael Overdorf as Chief Business Officer.   GlobeNewswire Inc
Jul 28, 2020
04:05PM EDT  Annexon Announces Closing of Initial Public Offering   GlobeNewswire Inc
Jul 24, 2020
01:25PM EDT  Annexon IPO Opens at $17.40, Priced at $17.00   Benzinga
10:56AM EDT  Annexon Indicated To Open At $18.50   Benzinga
05:34AM EDT  Annexon Prices 14.8M Shares IPO @ $17/Share   Benzinga


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC